Parkside Financial Bank & Trust Has $285,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Parkside Financial Bank & Trust trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,256 shares of the medical instruments supplier’s stock after selling 92 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Becton, Dickinson and Company were worth $285,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in BDX. Assenagon Asset Management S.A. boosted its holdings in Becton, Dickinson and Company by 10.5% during the third quarter. Assenagon Asset Management S.A. now owns 8,027 shares of the medical instruments supplier’s stock valued at $1,935,000 after purchasing an additional 766 shares in the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $304,000. Diversify Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 18.4% in the third quarter. Diversify Wealth Management LLC now owns 2,452 shares of the medical instruments supplier’s stock valued at $590,000 after acquiring an additional 381 shares during the last quarter. US Bancorp DE raised its stake in shares of Becton, Dickinson and Company by 12.4% in the third quarter. US Bancorp DE now owns 83,383 shares of the medical instruments supplier’s stock valued at $20,104,000 after acquiring an additional 9,190 shares during the last quarter. Finally, Deroy & Devereaux Private Investment Counsel Inc. raised its stake in shares of Becton, Dickinson and Company by 16.9% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 131,105 shares of the medical instruments supplier’s stock valued at $31,609,000 after acquiring an additional 18,958 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $225.57 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company has a 50 day moving average price of $233.08 and a 200 day moving average price of $233.05. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The stock has a market capitalization of $64.77 billion, a PE ratio of 37.47, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.84%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the sale, the director now owns 36,033 shares of the company’s stock, valued at approximately $8,215,163.67. The trade was a 1.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,544 shares of company stock valued at $2,370,309. Company insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BDX. Barclays lifted their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.